Clinical Trial Update: Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nicotinamide riboside for renal protection in patients with SARS-CoV-2 infection and acute kidney injury completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Nicotinamide Riboside (nicotinamide riboside)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: SARS-CoV-2 Infection, Acute Kidney Injury | Phase 2 | Status: COMPLETED | Results posted: 2023-12-26